Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2011.07.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19.
Arch Pharm Res
January 2025
College of Pharmacy, Dongguk University-Seoul, Goyang, 10326, Republic of Korea.
Article Synopsis
- Gliclazide is a medication for type 2 diabetes, primarily metabolized by genetic variations in the CYP2C9 and CYP2C19 enzymes.
- A physiologically based pharmacokinetic (PBPK) model was developed to analyze how these genetic differences affect gliclazide's effects in patients.
- The model accurately predicted drug concentration levels in the bloodstream, meeting standard evaluation criteria and potentially paving the way for personalized treatment plans based on genetic profiles.
Hypothesized pharmacogenomic and medication influences on tetrahydrocannabinol and cannabidiol metabolism in a cohort of unselected oral cannabis users.
J Cannabis Res
January 2025
Division of General Internal Medicine, Mayo Clinic College of Medicine and Science, 200 First St SW, Rochester, MN, 55905, USA.
Background: Differences in cannabinoid metabolism and patient responses can arise even with equivalent doses and formulations. Genetic polymorphisms in genes responsible for cannabinoid metabolism and medications that alter CYP450 pathways responsible for metabolism of cannabinoids may account for some of this variability.
Materials And Methods: A retrospective chart review was conducted on a cohort of unselected patients who had previously completed pharmacogenomic testing and reported oral cannabis use, as defined as "oral" or "by mouth" route of administration.
Introduction: Combination of clopidogrel and aspirin has been proven beneficial in treating symptomatic intracranial stenosis. The CYP2C19 polymorphism (CYP2C19*1, CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles) affects the efficacy of clopidogrel. Although epidemiologic studies of CYP2C19 polymorphism have been conducted in the Thai population, data on the frequency of allelic variants of CYP2C19 in Thai patients with symptomatic intracranial stenosis are lacking.
View Article and Find Full Text PDFPharmacogenomic landscape of the Thai population from genome sequencing of 949 individuals.
Sci Rep
December 2024
National Biobank of Thailand, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, Thailand.
Inter-individual variability in drug responses is significantly influenced by genetic factors, underscoring the importance of population-specific pharmacogenomic studies to optimize clinical outcomes. In this study, we analyzed whole genome sequencing data from 949 unrelated Thai individuals and conducted an in-depth analysis of 3239 genes involved in drug pharmacokinetics, pharmacodynamics, or immune-mediated adverse drug reactions. We identified 43 single nucleotide polymorphisms (SNPs), 134 diplotypes, and 15 human leukocyte antigen (HLA) alleles, all with moderate to high clinical significance.
View Article and Find Full Text PDFPEAR1, PON1, CYP2C19, CYP1A2 and F2R Polymorphisms are Associated with MACE in Clopidogrel-Treated Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Pharmgenomics Pers Med
December 2024
Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, People's Republic of China.
Objective: The objective of this study was to evaluate the impact of clopidogrel-related gene polymorphisms on the occurrence of recurrent thrombotic events and cardiovascular death in patients with acute coronary syndrome (ACS) following percutaneous coronary intervention (PCI).
Methods: We conducted genotype testing for 26 specific loci mapped to 18 clopidogrel-associated genes in ACS patients who had undergone PCI and were receiving dual antiplatelet therapy only involving clopidogrel. We documented major adverse cardiovascular events (MACE) and clinical endpoints, analyzing the effect of genetic polymorphisms on treatment outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!